Intraperitoneal chemotherapy strategies in the treatment of epithelial ovarian carcinoma

Current Opinion in Obstetrics and Gynecology

Volumn 11, Issue 1, 1999, Pages 23-27

  Makhija, Sharmila ^a   Sabbatini, Paul ^a   Barakat, Richard R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIBODY; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DOXORUBICIN; ETOPOSIDE; FLOXURIDINE; FLUOROURACIL; GEMCITABINE; IRINOTECAN; LIPOSOME; LUTETIUM; MEMBRANE ANTIGEN; MITOXANTRONE; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; RECOMBINANT GAMMA INTERFERON; TAXANE DERIVATIVE; TOPOTECAN; TUMOR NECROSIS FACTOR ALPHA;

ADENOVIRUS; ANEMIA; ARTHRALGIA; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL TRIAL; DOSE RESPONSE; DRUG PENETRATION; FEMALE; GASTROINTESTINAL SYMPTOM; GENE THERAPY; HUMAN; IMMUNIZATION; IMMUNOTHERAPY; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MULTIDRUG RESISTANCE; NONHUMAN; ORAL DRUG ADMINISTRATION; OVARY CARCINOMA; PARACENTESIS; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA; CLINICAL TRIALS; FEMALE; HUMANS; INJECTIONS, INTRAPERITONEAL; OVARIAN NEOPLASMS;

EID: 0033001333     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001703-199901000-00005     Document Type: Article

References (28)

1. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N Engl J Med 1996; 334:1-6
2. Markman M, Reichman B, Hakes T, Jones W, Lewis JL Jr, Rubin S, et al. Responses to second line cisplatin based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin J Clin Oncol 1991; 9:1801-1805.
3. Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996; 335:1950-1955.
4. Barakat RR, Fennelly D, Pizzuto F, Venkatraman ES, Brown C, Curtin JP •• Salvage intraperitoneal therapy of advanced epithelial ovarian cancer: impact of retroperitoneal nodal disease. Eur J Gynaecol Oncol 1997; 18:161-163. Addresses the issue of retroperitoneal lymph node involvement in ovarian cancer and the effectiveness of cancer and intraperitoneal chemotherapy.
5. Dedrick RL, Flessner MF. Pharmacokinetic problems in peritoneal drug •• administration, tissue penetration and surface exposure. J Natl Cancer Inst 1997; 89:480-487. Recent update of the mathematical model that predicts ideal charateristics of intraperitoneal agents.
6. Francis P, Rowinsky E, Schneider J, Hakes T, Hoskins W, Markman M. Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot study. J Clin Oncol 1995; 13:2961-2967.
7. Markman M, Rowinsky E, Hakes T, Reichman B, Jones W, Lewis JL Jr, et al. Phase I trial of intraperitoneal Taxol: a Gynecologic Oncology Group study. J Clin Oncol 1992; 10 1485-1491.
8. Markman M, George M, Hakes T, Reichman B, Hoskins W, Rubin S, et al. Phase Il trial of intraperitoneal mitoxantrone in the management of refractory ovarian carcinoma. J Clin Oncol 1990; 8:146-150.
9. Muggia FM, Liu PY, Alberts DS, Wallace DL, O'Toole RV, Terada KY, et al Intraperitoneal mitoxantrone or floxuridine: effects on time-to-failure and survival in patients with minimal residual ovarian cancer after second look laparotomy - a randomized phase II study by the Southwest Oncology Group. Gynecol Oncol 1996; 61:395-402.
10. Markman M, Blessing JA, Major F, Manetta A. Salvage intraperitoneal therapy of ovarian cancer employing cisplatin and etoposide, a Gynecologic Oncology Group study. Gynecol Oncol 1993; 50:191-195.
11. Braly PS, Berek JS, Blessing JA, Homesley HD, Averette H. Intraperitoneal administration of cisplatin and 5-fluorouracil in residual ovarian cancer: a phase II Gynecologic Oncology Group Trial. Gynecol Oncol 1995; 56.164-168.
12. Muggia FM, Jeffers S, Muderspach L, Roman L, Rosales R, Groshen S, et al. Phase I/II study of intraperitoneal floxuridine and platinums (cisplatin or carboplatin). Gynecol Oncol 1997; 66:290-294
13. Topuz E, Aydiner A, Saip P, Bengisu E, Berkman S, Disci R, et al. Intraperitoneal cisplatin-mitoxantrone in ovarian cancer patients with minimal residual disease. Eur J Gynaecol Oncol 1997; 18:71-75.
14. Bruzzone M, Rubagotti A, Gadducci A, Catsafados E, Foglia G, Brunetti I, et al. Intraperitoneal carboplatin with or without interferon-alpha in advanced ovarian cancer patients with minimal residual disease at second look: a prospective randomized trial of 111 patients Gruppo Oncologic Nord Ovest. Gynecol Oncol 1997; 65:499-505.
15. Chambers SK, Chambers JT, Davis CA, Kohorn EI, Schwarte PE, Lorber MI, et al Pharmacokinetic and phase I trial of intraperitoneal carboplatin and cyclosporine in refractory ovarian cancer patients. J Clin Oncol 1997; 15:1945-1952.
16. Peters GJ, Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Braakhuis BJ, et al. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 1995; 22:72-79.
17. Steward WP, Dunlop DJ, Dabouis G, Lacroix H, Talbot D, et al. Phase I/II study of gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer: preliminary results. Semin Oncol 1996; 23:43-47.
18. Shapiro JD, Millward MJ, Rischin D, Michael M, Walcher V, Francis PA, et al. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol 1996; 63 89-93.
19. Green MR. Gemcitabine safety overview. Semin Oncol 1996; 23:32-35.
20. Le Chevlier T. Single agent activity of gemcitabine in advanced non-small cell lung cancer. Semin Oncol 1996; 23:36-42.
21. Sadzuka Y, Nakai S, Miyagishima A, Nozawa Y, Hirota S Effects of administered route on tissue distribution and antitumor activity of polyethyleneglycol-coated liposomes containing adriamycin. Cancer Lett 1997; 111:77-86.
22. Kanter PM, Klaich G, Bullard GA, King JM, Pavelic ZP. Preclinical toxicology study of liposome encapsulated doxorubicin given intraperitoneally to dogs. In Vivo 1994; 8:975-982
23. Xing X, Liu V, Xia W, Stephens LC, Huang L, Lopez-Berestein G, et al. Safety studies in the intraperitoneal injection of E1A-liposome complex. Gene Ther 1997; 4:238-243.
24. Pratesi G, Tortoreto M, Corti C, Giardini R, Zunino F. Successful local regional therapy with topotecan of intraperitoneally growing human ovarian cancer xenografts Br J Cancer 1995; 71.525-528.
25. Pujade-Lauraine E, Guastalla JP, Colombo N, Devillier P, Francois E, Fumoleau P, et al. Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second look laparotomy. J Clin Oncol 1996, 14:343-350
26. Hirte HW, Miller D, Tonkin K, Findlay B, Capstick V, Murphy J, et al A randomized trial of paracentesis plus intraperitoneal tumor necrosis factor-alpha versus paracentesis alone in patients with symptomatic ascites from recurrent ovarian carcinoma Gynecol Oncol 1997; 64:80-87.
27. Alvarez RD, Partridge EE, Khazaeli MB, Plott G, Austin M, Kilgore L, et al. • Intraperitoneal radioimmunotherapy of ovarian cancer with 177LU-CC49. a phase I/II study. Gynecol Oncol 1997;65:94-101. Addresses the effectiveness of intraperitoneal radioimmunotherapy in cisplatin-resistant ovarian cancer patients.
28. Deshane J, Siegal GP, Wang M, Wright M, Bucy RP, Alvarez RD, et al. Transductional efficacy and safety of an intraperitoneally delivered adenovirus encoding an anti-erbB-2 intracellular single chain antibody for ovarian cancer gene therapy. Gynecol Oncol 1997; 64:378-385.